Multiple Sclerosis Awareness Month: Latest research, treatments from ACTRIMS 2024

March is Multiple Sclerosis Awareness Month, a time to improve knowledge of and highlight the growing treatment options for progressive types of this degenerative disease.

Like other experts, researchers from the Hackensack Meridian Neuroscience Institute are studying several promising experimental therapies for MS, including CAR T-cell therapy and BTK inhibitors, according to a press release from Hackensack Meridian Health.

In honor of Multiple Sclerosis Awareness Month, Healio has gathered the latest research and updates on treatments for the disease.

Clemastine fumarate linked to accelerated disability progression in MS

Treatment with clemastine fumarate was linked to accelerated disease and disability progression due to pyroptosis in a small cohort of individuals with multiple sclerosis, according to a presenter at ACTRIMS 2024. Read more.

Evobrutinib nonsuperior to teriflunomide for relapsing forms of MS

Treatment with evobrutinib was nonsuperior to teriflunomide in confirmed disability progression at 12 and 24 weeks for those with relapsing forms of multiple sclerosis, according to a presenter at ACTRIMS 2024. Read more.

‘Wearing off’ monoclonal antibodies leads to patient dissatisfaction, depression in MS

The “wearing-off” effect with monoclonal antibodies prescribed for multiple sclerosis led to treatment dissatisfaction and was associated with depression, according to a poster from ACTRIMS 2024. Read more.

Patient-recorded home video feasible method to assess gait kinematics in MS

In-home video taken by adults with multiple sclerosis is a feasible and valid method to determine the mechanism and motion of their gait, according to a poster from ACTRIMS 2024. Read more.

Speech pauses in multiple sclerosis may indicate cognitive impairment

Variability and length of pauses in speech may indicate cognitive impairment for German-speaking individuals with multiple sclerosis, according to a poster from ACTRIMS 2024. Read more.

Survey reveals disparities in MS knowledge, care among physicians

Among residents and attending physicians at an Ivy League medical center, disparities exist in knowledge and understanding of care for those with multiple sclerosis, according to a poster from ACTRIMS 2024. Read more.

Better sleep linked to improved verbal memory in multiple sclerosis

In two separate cohorts of individuals with multiple sclerosis and memory issues, better sleep was linked to improved verbal memory, according to a poster at ACTRIMS 2024. Read more.

Machine learning model could assist in treatment of MS

Application of a machine learning model to databases of patients with multiple sclerosis expanded understanding of disease progression, according to a poster at ACTRIMS 2024. Read more.

Relapses reduced by 67% after 72 months with ozanimod in patients with multiple sclerosis

In an open-label extension, treatment with ozanimod demonstrated sustained efficacy for disease progression in patients with relapsing multiple sclerosis, per research presented at ACTRIMS 2024. Read more.

Vidofludimus calcium linked to fatigue reduction, may have long-term effect in MS

Oral administration of vidofludimus calcium reduced fatigue over 14 days compared with placebo and may have a long-term positive effect in multiple sclerosis, according to a poster presented at ACTRIMS 2024. Read more.

Reference:

• Newswise. Hackensack Meridian Neuroscience Institute Leading the Way in Comprehensive Multiple Sclerosis Research. https://www.newswise.com/articles/hackensack-meridian-neuroscience-institute-leading-the-way-in-comprehensive-multiple-sclerosis-research. Accessed March 22, 2024.